Mizuho Securities Maintains Underperform Rating & $8 PT on Valeant Pharma (VRX); 'Rhetoric Changes but Situation Doesn't... Significant Downside Risk to Equity'
Tweet Send to a Friend
Mizuho Securities maintains Underperform rating and $8 PT on Valeant Pharmaceuticals (NYSE: VRX), following a review of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE